Lexaria Bioscience (LEXX) Enterprise Value Growth (1y) (2011 - 2026)
Lexaria Bioscience (LEXX) Enterprise Value Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 22.79% |
| Feb 28, 2026 | 20.31% |
| Nov 30, 2025 | 43.35% |
| Aug 31, 2025 | 67.85% |
| May 31, 2025 | 43.58% |
| Feb 28, 2025 | -34.08% |
| Nov 30, 2024 | -254.64% |
| Aug 31, 2024 | -273.40% |
| May 31, 2024 | -134.46% |
| Feb 29, 2024 | -33.07% |
| Nov 30, 2023 | 53.31% |
| Aug 31, 2023 | 71.56% |
| May 31, 2023 | 50.22% |
| Feb 28, 2023 | 57.56% |
| Nov 30, 2022 | 55.78% |
| Aug 31, 2022 | 45.82% |
| May 31, 2022 | 11.38% |
| Feb 28, 2022 | 7.47% |
| Nov 30, 2021 | -1,753.65% |
| Aug 31, 2021 | -781.53% |